Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

NCR graphs - Age specific incidence rates

- All cancer age-specific incidence rates, including non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, including non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- Oesophagus cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Oesophagus cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Estomac cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Estomac cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Colo-rectal cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Colo-rectal cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Liver cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Liver cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Pancreas cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Pancreas cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Larynx cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Larynx cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Trachea-bronchus-lung cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Trachea-bronchus-lung cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bone cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bone cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Melanoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Melanoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-melanoma skin cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-melanoma skin cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Breast cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Breast cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Col uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Corpus uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Ovary cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Prostate cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Testis cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015

- Kidney cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Kidney cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bladder cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bladder cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Brain and central nervous system cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Brain and central nervous system cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Thyroid cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Thyroid cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Hodgkin's lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Hodgkin's lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-Hodgkin lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-Hodgkin lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Multiple Myeloma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Multiple Myeloma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Lymphoid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Lymphoid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Myeloid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Myeloid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
 
    ...
    153
    ...
ATC Name B/G Ingredients Dosage Form Price
B02BX01 DICYNONE B Etamsylate - 500mg 500mg Capsule 1,311,590 L.L
J07AL02 SYNFLORIX B Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg Injectable suspension 4,675,228 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
P02CA01 VERMOX B Mebendazole - 100mg/5ml 100mg/5ml Suspension 223,078 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 1mcg 1mcg Capsule 3,735,882 L.L
D10AD04 ROACCUTANE B Isotretinoin - 0.05% 0.05% Gel 932,627 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
M01AB16 AIRTAL 100MG 20 B Aceclofenac - 100mg 100mg Tablet, film coated 471,689 L.L
N03AX09 LAMICTAL B Lamotrigine - 50mg 50mg Tablet 1,753,895 L.L
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 25mg 25mg Tablet, film coated 75,701,015 L.L
D10AD06 AKLIEF B Trifarotene - 50mcg/g 50mcg/g Cream 4,359,425 L.L
J07AL02 PREVENAR 20 B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F,8, 9V,10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F, 33F (2.2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein (approximately 51mcg) adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 7,415,107 L.L
L01ED03 ALECENSA B Alectinib - 150mg 150mg Capsule, hard 490,837,809 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 190,826 L.L
V03AC03 JADENU B Deferasirox - 180mg 180mg Tablet, film coated 27,151,164 L.L
A08AA01 LOMAIRA B Phentermine Hydrochloride - 8mg 8mg Tablet 6,138,673 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.25mcg 0.25mcg Capsule 1,138,235 L.L
J07AL02 VAXNEUVANCE B Pneumococcal polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 22F, 23F,33F (2mcg) Pneumococcal polysaccharide for serotypes 6B (4.4mcg) Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate adjuvant - Injectable suspension 6,988,413 L.L
L01ED04 ALUNBRIG B Brigatinib - 30mg 30mg Tablet, film coated 124,685,776 L.L
R05X ACTISOUFRE B Sulfure de Sodium - 13mg, Saccharomyces Cerevisiae - 500mg Solution 740,457 L.L
A08AA62 CONTRAVE B Naltrexone Hydrochloride - 8mg, Bupropion Hydrochloride - 90mg Tablet, prolonged release 11,653,550 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 943,377 L.L
B02BX05 REVOLADE B Eltrombopag Olamine - 50mg 50mg Tablet, film coated 151,399,262 L.L
J07AP03 TYPHIM VI B Salmonella typhi polysaccharides - 0.025mg/0.5ml 0.025mg/0.5ml Injectable solution 1,118,077 L.L
L01ED04 ALUNBRIG B Brigatinib - 90mg 90mg Tablet, film coated 374,059,747 L.L
R05X FERVEX CHILDREN SUGAR FREE B Paracetamol - 280mg, Ascorbic acid - 100mg, Pheniramine maleate - 10mg Granules for solution 425,998 L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
A11CC03 ONE-ALPHA B Alfacalcidol - 0.5mcg 0.5mcg Capsule 942,034 L.L
    ...
    153
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026